Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Multi-dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) with or Without Recombinant Human Interleukin-2 (rhIL-2) in Adults with Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission with Minimal Residual Disease (MRD) or Relapsed/refractory (R/R) AML

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04310592
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:03.080595+00:00
Published At
2024-12-12T00:00:00+00:00
Record Updated At
2024-12-12
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Leukemia", "Leukemia, Myeloid", "Leukemia, Myeloid, Acute", "Neoplasms by Histologic Type", "Neoplasms", "Immunosuppressive Agents", "Immunologic Factors", "Physiological Effects of Drugs", "Alkylating Agents", "Antimetabolites, Antineoplastic", "Antiviral Agents", "Analgesics, Non-narcotic", "Anti-infective Agents", "Analgesics", "Peripheral Nervous System Agents", "Hematologic Diseases", "Hematologic Neoplasms", "Leukemia in Remission", "Relapsed Adult AML", "Refractory AML"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-12-12"
protocolSection.identificationModule.nctId
"NCT04310592"
protocolSection.identificationModule.officialTitle
"A Phase I Multi-dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) with or Without Recombinant Human Interleukin-2 (rhIL-2) in Adults with Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission with Minimal Residual Disease (MRD) or Relapsed/refractory (R/R) AML"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Leukemia (protocolSection.conditionsModule.conditions)
  • Leukemia, Myeloid (protocolSection.conditionsModule.conditions)
  • Leukemia, Myeloid, Acute (protocolSection.conditionsModule.conditions)
  • Neoplasms by Histologic Type (protocolSection.conditionsModule.conditions)
  • Neoplasms (protocolSection.conditionsModule.conditions)
  • Immunosuppressive Agents (protocolSection.conditionsModule.conditions)
  • Immunologic Factors (protocolSection.conditionsModule.conditions)
  • Physiological Effects of Drugs (protocolSection.conditionsModule.conditions)
  • Alkylating Agents (protocolSection.conditionsModule.conditions)
  • Antimetabolites, Antineoplastic (protocolSection.conditionsModule.conditions)
  • Antiviral Agents (protocolSection.conditionsModule.conditions)
  • Analgesics, Non-narcotic (protocolSection.conditionsModule.conditions)
  • Anti-infective Agents (protocolSection.conditionsModule.conditions)
  • Analgesics (protocolSection.conditionsModule.conditions)
  • Peripheral Nervous System Agents (protocolSection.conditionsModule.conditions)
  • Hematologic Diseases (protocolSection.conditionsModule.conditions)
  • Hematologic Neoplasms (protocolSection.conditionsModule.conditions)
  • Leukemia in Remission (protocolSection.conditionsModule.conditions)
  • Relapsed Adult AML (protocolSection.conditionsModule.conditions)
  • Refractory AML (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.